Radionuclide Therapy in Malignant Thyroid Diseases: Differentiated Thyroid Cancer
Radionuclide Therapy, Springer International Publishing Ag, ss.97-134, 2022
- Yayın Türü: Kitapta Bölüm / Araştırma Kitabı
- Basım Tarihi: 2022
- Doi Numarası: 10.1007/978-3-030-97220-2_6
- Yayınevi: Springer International Publishing Ag
- Sayfa Sayıları: ss.97-134
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
According to “Turkey Cancer Statistics” published by the Public Health Directorate of the Ministry of Health in Turkey, thyroid cancers rank second in all age groups in women in Turkey after breast cancer, first in girls and women between the ages of 15 and 24 and fifth in boys [1]. The project, which was created to provide up-to-date estimates about the incidence, mortality, and prevalence of major cancer types at the national level in many countries of the world, ranks 4th in all age groups in women in the USA according to Globocan 2012 data [2]. According to the SEER (Surveillance, Epidemiology and End Results) data, the number of thyroid cancer cases per 100, 000 people in 1992 was 5.8, while it was reported as 14.6 in 2015. With 53, 990 new cases in 2018, it is estimated that it will constitute 3.1% of all cancers [3]. The reason for the increase in the incidence of thyroid cancer is an increase in actual disease formation due to ionized radiation, environmental factors, eating habits and obesity, as well as an improvement in diagnostic standards and medical experience [4-6]. Lim et al. reported in their study on the incidence of thyroid cancer and mortality rate in the USA between 1974 and 2013; it was found that with the real increase in papillary thyroid carcinoma (PTC), an increase in the mortality rate was observed in advanced PTC cases, despite all standard, adjuvant treatments and systemic treatments. The authors stated that clinical trials were needed to optimize new systemic therapies in advanced DTC, including iodine-resistant PTC [6].